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Background: Vascular endothelial growth factor (VEGF)-D has been shown to promote lymph node metastasis
in several cancers. Although generally overexpressed in ovarian carcinoma, its role in nodal dissemination of this
cancer is unclear. To clarify the role of VEGF-D and the underlying molecular mechanisms, we investigated the
function of VEGF-D using a mouse xenograft model of ovarian cancer.
Methods: Human ovarian serous adenocarcinoma SKOV3 cells were transfected with VEGF-D recombinant plasmid
DNA, or with control vectors. The cells were injected subcutaneously into the footpads of nude mice. Tumor growth was
evaluated weekly. Draining lymphatics were observed grossly with Evan’s blue lymphangiography. Tumoral lymphatics
were delineated with both Evan’s blue and LYVE-1 immunostaining. Tumor metastases to lymph nodes were evaluated
by H&E and CA125/CD40 staining. Expression of VEGF-D in primary tumors and levels of CA125 in involved lymph nodes
were examined by immunohistochemistry. Tumor cell apoptosis was analyzed by Hoechst dyeing.
Results: Mice bearing VEGF-D overexpressing xenografts showed a significantly higher rate of lymph node metastasis
and markedly greater tumor volume compared with the controls. The functional lymphatic vessels were denser and
enlarged in marginal and central tumor portions. Additionally, higher CA125 expression was observed in the involved
lymph nodes. Mice bearing VEGF-D overexpressing xenografts also exhibited a markedly lower apoptotic index
compared with the controls.
Conclusions: Our data demonstrate the important role of VEGF-D in promoting lymph node metastasis by increasing
tumor lymphangiogenesis, stimulating draining lymphatic vessel formation, and enhancing tumor invasiveness. Our
findings show that VEGF-D can be a promising therapeutic target for ovarian cancer.
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Lymph node metastasis is a major biological character-
istic of ovarian malignancies and is commonly seen in
advanced stage ovarian cancer with an incidence of
67.2% in para-aortic and pelvic lymph node metastasis.
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reproduction in any medium, provided the oris seen in 10% to 30% of the cases [1,2]. Lymph node
status is an important predictor of poor prognosis in
patients with ovarian carcinoma [3-5]. Patients with
positive lymph node have a significantly shorter overall
survival than node-negative patients [1]. Moreover, recent
investigations have shown that the absence of lymph
node metastases is associated with lack of distant organ
metastases, highlighting a critical role of lymph node
metastasis in tumor dissemination [6]. Currently, there
are no effective therapeutic strategies against lymph
node metastasis. Pelvic and para-aortic lymphadenectomyThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited.
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early-stage ovarian cancer patients due to complications
and associated morbidities [7,8].
The finding of vascular endothelial growth factors
(VEGF) mediating lymphangiogenesis and thereby pro-
moting lymphatic metastasis in tumors provides a new
therapeutic target. Of all the prolymphangiogenic fac-
tors, VEGF-D is a major effector. VEGF-D, also known
as c-fos-induced growth factor, is a secreted growth
factor consisting of VEGF-homology domain, receptor
binding domains, and propeptides in both termini.
After secretion into the extracellular space, the C–
and N-terminal propeptides are cleaved from full length
VEGF-D to form mature VEGF-D. This proteolytic pro-
cessing increases the affinity of VEGF-D for VEGFR-3, a
tyrosine kinase receptor that is mainly located on adult
lymphatic endothelium and is implicated in lymphangio-
genesis [9,10]. VEGF-D also interacts with a non-tyrosine
kinase receptor Nrp-2, another lymphangiogenesis-
associated factor [11]. A prominent role of VEGF-D
in lymph node metastasis is supported by findings
from several studies of cancer [12-15], but not by
others [16-18].
In patients with epithelial ovarian carcinoma, VEGF-D
expression has been shown to be a predictor of poor
outcome [3,4]. We hypothesized that VEGF-D may be a
potent promoter of lymphatic metastasis of ovarian can-
cer cells. In the current study, we examined the potential
effects of VEGF-D overexpression on ovarian carcinoma
growth and lymphangiogenesis by using a mouse model




Female athymic nude mice (7–8 weeks of age, 18–20
grams) were obtained from the Animal Center of Sichuan
University, Sichuan, China and housed in environmentally
controlled conditions (22°C, a 12 h light/dark cycle with
the light cycle from 6:00 to 18:00) with ad libitum access
to standard rodent chow and water. The study protocol
was approved by the local institutional review board at the
authors’ affiliated institution and all animal experiments
were performed in accordance with the National Animal
Care and Use Guidelines of the US National Institute
of Health (NIH).
Generation of cell line stably expressing VEGF-D
Human epithelial serous cystadenocarcinoma SKOV3 cells
(American Type Culture Collection, Manassas, VA) were
grown in RPMI-1640 with 10% fetal bovine serum. The
cells were transfected with a vector containing a mouse
VEGF-D cDNA (GenBank NM_010216 GI: 6753873) or
with the control vector pcDNA3.1(+) (Invitrogen, Carlsbad,CA). Stable cells expressing VEGF-D, designated SKOV3/
VEGF-D, or control cells, designated SKOV3/pcDNA were
established after selection with 50 μg/mL geneticin (Sigma,
St. Louis, MO).
RT-PCR
Total RNA was prepared from 1 × 107 cells. First strand
cDNA was synthesized and then amplified with PCR
consisting of the following cycles: 94°C for 30 s; 55°C
for 30 s; and 72°C for 1.5 min for a total of 30 cycles.
The VEGF-D gene was amplified using the following
primers: 5′-GCAAGCTTATGTATGGAGAATGGGGAA
TG-3′, sense, and 5′-CGTCTAGATCAAGGGTTCTCCT
GGCTG-3′, antisense. The PCR products were visualized
by gel electrophoresis. The expression of VEGF-D was
normalized against β-actin.
Animal experiments
Totally, 1.5 × 106 cells (suspended in 50 μL serum-free
medium) were injected into the left hind-footpads of
mice. The experiments were carried out for three times
independently with six mice in each group. Tumor
growth and sentinel lymph nodes were evaluated
weekly. Tumor volume was determined using the fol-
lowing formula: tumor volume (mm3) = 0.52 × length
(mm) ×width (mm) × height (mm). Mice were sacrificed
after 12 to 15 weeks. Lymph nodes, labeled by their loca-
tions, as well as primary tumors, were collected, fixed in
formalin, and embedded in paraffin.
Lymphatic vessel discrimination
Lymphatic vessels were grossly observed using Evan’s blue.
Briefly, before the mice were sacrificed, Evan’s blue was
injected subcutaneously into the tumors of the footpads
until the inguinal lymph nodes were marked. Then, an
additional 5 μL of the dye was injected. The draining
lymphatic vessels of inguinal trunk along the milk line
were scored as: negative (−) if not visualized or vague, and
positive (+) if clearly seen and enlarged.
Microscopic lymphatic vessel estimation was performed
by immunostaining with antibody against LYVE-1 as
detailed below. The LYVE-1-positive lymphatic vessels
were counted microscopically under 400× magnification
in three separate areas of the highest vascular density
(vascular ‘hot spots’) per Section. A comparative analysis
of the number of lymphatic vessels in intra- and peri-
tumoral areas was performed.
Immunostaining
Mice were sacrificed after 12 to 15 weeks. Lymph nodes,
labeled by their locations, as well as primary tumors, were
collected, fixed in formalin, and embedded in paraffin. Im-
munostaining of VEGF-D, LYVE-1, CA125, and CD40 was
performed using a streptavidin-biotin-peroxidase complex
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antibodies were used: rat anti-mouse VEGF-D monoclonal
antibody (R&D Systems), goat anti-mouse polyclonal
LYVE-1 antibody (Santa Cruz Biotechnology, Santa Cruz,
CA), mouse anti-human CA125 monoclonal antibody
(Zhongshan-Golden Bridge, Beijing, China), and mouse
anti-human CD40 monoclonal antibody (Santa Cruz
Biotechnology). Biotin-conjugated secondary antibodies
were from Boster Bio. Sections were counterstained
with hematoxylin. Background binding was determined
by omission of the primary antibody.
VEGF-D and CA125 immunostaining was evaluated
under a light microscope independently by two experi-
enced pathologists. VEGF-D and CA125 reactivity was
defined as granular and diffuse cytoplasmic, membran-
ous or nuclear staining and evaluated according to
intensity and proportion. The intensity of staining was
scored as follows: negative (±), 0-25% positive cells; weak
(+), >25–50% positive cells; moderate (++), >50–75%
positive cells; strong (+++), >75% positive cells. The
photographs were taken using a Leica digital microscope
color camera (DFC295, Germany) at 20×-magnification
of objective lens by Leica light microscope (DM2500,
Germany) with a total magnification of 400×.
Evaluation of lymphatic metastasis
Lymph nodes were harvested, fixed in formalin, and em-
bedded in paraffin. Each lymph node was labeled with
its location: popliteal, parailiac, renal hilum, inguinal, or
axillary node. Metastases were examined by hematoxylin
and eosin (H&E) staining. Atypical morphological metas-
tasis was further verified by CA125 or CD40 immuno-
staining [19-21]. Lymph node metastases were assessed by
two pathologists in a blinded manner, and expressed as a
ratio of metastatic lymph nodes out of the total number of
lymph nodes.
Apoptosis analysis
Tissue sections were deparaffinized and rehydrated through
xylene, gradient ethanol, and distilled water. After rinsing
three times in PBS, the tissue sections were incubated with
1 μmol/L Hoechst-33258 (Sigma) for ten minutes. After
washing three times in PBS, slides were transferred to
coverslip with antifade solution (Sigma), and then analyzed
by fluorescence microscopy. Cells with condensed chroma-
tin or fragmented nuclei emitting intense blue fluorescence
were classified as apoptotic.
Statistical analysis
Statistical analyses were carried out with the SPSS software
version 15.0 (SPSS Inc., Chicago, IL). The relationship
of VEGF-D with lymph node metastasis was evaluated
using Fisher’s exact or Pearson Chi-Square tests. Student-
Newman-Keuls test was used to examine homogeneity.Tumor volume, lymph vessel density and apoptosis index
were analyzed using univariate analysis of variance.
Comparison of ranked data (e.g., VEGF-D or CA125
expression) was performed using Kruskal-Wallis Test.
Continuous variables are given as mean ± SD. P < 0.05
was considered statistically significant.
Results
VEGF-D overexpression promotes growth of ovarian
cancer xenografts
Efficiency and selectivity of the vectors was verified by
RT-PCR (Figure 1A). Immunohistochemistry showed that
mouse xenografts bearing SKOV3/VEGF-D cells exhibited
apparent strong staining of VEGF-D in both the cytoplasm
and nuclei of the tumor cells while only weak or negative
staining of VEGF-D was observed in mouse xenografts
bearing SKOV3 cells or SKOV3/pcDNA cells (Figure 1B
to 1G).
Xenografts bearing SKOV3 cells overexpressing VEGF-D
grew at an apparent faster pace from week 3 post in-
oculation compared to xenografts bearing SKOV3 cells
or SKOV3 cells transfected with control vectors. By
week 5, the tumor volume in VEGF-D overexpressing
xenograft was significantly greater than that of xeno-
grafts bearing SKOV3 cells or SKOV3 cells transfected
with control vectors (P < 0.05) (Figure 1H).
VEGF-D overexpression promotes lymphangiogenesis in
mouse xenografts
In comparison to mouse xenografts bearing SKOV3
cells or SKOV3 cells transfected with control vectors,
xenografts bearing SKOV3 cells overexpressing VEGF-
D showed grossly dilated lymphatic vessels (Figure 2).
Lymphatic vessels were not prominent on the tumor
surface in mice bearing SKOV3 cells or SKOV3 cells
transfected with control vectors. In contrast, the lymphatic
vessels were apparent and enlarged, with newly formed
lymphatic networks on the surface of tumors overexpress-
ing VEGF-D (Figure 2C and Table 1).
Immunostaining with an antibody against LYVE-1 (a
highly selective marker for lymphatic vessels) showed
numerous lymphatic vessels with open lumen in the
center of SKOV3 xenograft overexpressing VEGF-D, and
only sparse lymphatic vessels in SKOV3 or SKOV3/
pcDNA xenograft (Figure 3A to F). More significant
difference was found at the tumor margin (Figure 3G
to L). The lymphatic vessel density in VEGF-D overex-
pressing xenografts was much higher (55.83 ± 18.73 vs.
12.00 ± 3.46 for SKOV3 or15.83 ± 4.40 for SKOV3/pcDNA
xenografts; P < 0.001 for both) (Figure 3M). The lymphatic
vessel density at the margin of VEGF-D overexpressing
tumors was also significantly higher (128.67 ± 42.78 vs.
18.67 ± 5.35 for SKOV3 or17.17 ± 5.00 for SKOV3/pcDNA















Marker -actin VEGF- D
Figure 1 VEGF-D overexpression promotes mouse xenograft growth. (A) RT-PCR assays reveal the presence of VEGF-D mRNA transcripts
only in SKOV3 cells stably expressing VEGF-D (lane 7), not in SKOV3 cells (lane 5) or SKOV3 cells transfected with control vectors (lane 6). β-actin
was used as a loading control (lane 2, SKOV3 cells, lane 3, SKOV3 cells transfected with control vector, and lane 4, SKOV3 cells stably expressing
VEGF-D). (B-G) Immunostaining shows that VEGF-D is strongly expressed in the cytoplasm and nuclei of tumor cells stably expressing VEGF-D
from mouse xenografts (D and G) while it is only weakly expressed in SKOV3 cells or SKOV3 cells transfected with control vectors (B, C and F).
Magnification: ×400, scale bar = 200 μm. (H) Mice were inoculated subcutaneously with SKOV3, SKOV3 /pcDNA or SKOV3/VEGF-D cells. Tumor
growth was monitored by measuring tumor volume post inoculation. Data are expressed as mean ± SD of three independent experiments.
*P < 0.05 versus tumor xenografts bearing SKOV3 or SKOV3 transfected with control vectors.







Figure 2 VEGF-D promotes lymphangiogenesis. (A) Footpads bearing tumor xenografts are injected with Evan’s blue dye, which appears in
the lymph nodes (LNs) and lymphatic vessels (LVs). No Evans blue is observed in the blood vessels (BVs) and other adjacent tissues. (B) In the
drainage route from the inguinal to the axillary LN, mice bearing xenografts overexpressing VEGF-D show dilated LVs (right panel), while LVs in
mice bearing SKOV3 (left panel) or SKOV3/pcDNA (mid panel) xenografts show no apparent dilation. (C) LVs are not apparent on the tumor
surface in mice bearing SKOV3 (left panel) or SKOV3/pcDNA (mid panel) xenografts. LVs are apparent and enlarged and form new networks
(arrows) on the surface of tumors overexpressing VEGF-D.
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of ovarian cancer cells
Metastasis in the lymph nodes of mice bearing ovarian
cancer cells was apparent in H&E staining of lymph node
tissue sections (Figure 4A to D), as well as immunostain-
ing for CA125 or CD40 (Figure 4E to G). Furthermore,
100% (13/13) of the examined sentinel lymph nodes
in mice bearing VEGF-D overexpressing xenografts
contain tumor cells, whereas the rate of metastasis to
sentinel lymph node was only 62.5% (5/8) and 60% (6/10)
in mice bearing SKOV3 or SKOV3/pcDNA xenografts,Table 1 Gross staining by Evan’s blue dye of the inguinal





*P < 0.05 vs. mice bearing SKOV3 or SKOV3/pcDNA xenografts.respectively (P < 0.05 for both; Figure 4H). In an analysis
that included all lymph nodes, the metastasis rate was
90.9% (60/66) in mice bearing VEGF-D overexpressing
xenografts in contrast to 59.6% (31/52) and 60.5% (26/43)
in mice bearing SKOV3 or SKOV3/pcDNA xenografts,
respectively (P < 0.01 for both; Figure 4I).
VEGF-D overexpression upregulates CA125 in the
metastatic lymph nodes
CA125 expression was markedly enhanced in the sentinel
lymph nodes of mice bearing VEGF-D overexpressing
xenografts in comparison to that in mice bearing SKOV3
or SKOV3/pcDNA xenografts (Figure 5A). Many lymph
nodes in mice bearing VEGF-D overexpressing xenografts
were almost entirely occupied by CA125-positive tumor
cells (Figure 5A, right panel). The percentage of CA125-
positive area in the sentinel lymph nodes of mice bearing
VEGF-D overexpressing xenografts was approximately
2-fold higher than that of mice bearing SKOV3 or









Figure 3 VEGF-D overexpression promotes lymphangiogenesis. (A-L) Expression of LYVE-1 within and at the periphery of tumor tissues is
examined by immunohistochemistry. The region with the highest lymphatic vessel density is dotted in the black box (A-C and G-I) and shown
at higher magnification in D-F and J-L. Mean lymphatic vessel density ± SD of three independent experiments are shown in M and N. *P < 0.01
vs. mice bearing SKOV3 or SKOV3/pcDNA xenografts. Original magnification: ×400. Scale bar = 200 μm in A-C and G-I.
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positive for CA125 (++ or higher) was 69.2% (9/13) in mice
bearing xenografts overexpressing VEGF-D in contrast to
0% and 16.7% in mice bearing SKOV3 xenografts or
SKOV3/pcDNA xenografts (P < 0.01 for both; Table 2).
VEGF-D inhibits apoptosis of ovarian cancer cells
There was no difference in the apoptotic rate between
xenografts bearing SKOV3 (12.2 ± 1.94%) and xenografts
bearing SKOV3/pcDNA (10.6 ± 2.15%) (Figure 6A and B).
VEGF-D overexpressing xenografts showed a significantly
lower apoptotic index (3.2 ± 0.748%; P < 0.05) (Figure 6C
and D).
Discussion
Tumor metastasis to regional lymph nodes often rep-
resents the first step of tumor dissemination, which
precedes metastasis via the vascular system and serves
as a major prognostic indicator of tumor progression[22-24]. VEGF–C and VEGF-D act predominantly via
their receptor VEGFR-3, which is largely restricted to the
lymphatic endothelium in normal adult tissue [22]. VEGF-
C level correlates with active lymphangiogenesis, increases
lymphatic tumor spread to regional lymph nodes [25,26],
and decreases with decreasing activity of the VEGF-C/
VEGFR-3 signaling pathway [27,28].
VEGF-D could induce tumor-associated lymphangio-
genesis, and by doing so, promotes lymphatic spread
[4,12,13,29-31]. Such a notion was not supported by sev-
eral studies on breast cancer showing that VEGF-D has no
demonstrable effect on lymphangiogenesis or lymphatic
metastasis [18,32,33]. Niki et al. showed an inverse correl-
ation between VEGF-D and lymphogenous metastasis
in lung adenocarcinoma [16]. The role of VEGF-D in
lymphangiogenesis and lymphatic spread of ovarian
carcinoma remains controversial [3,4,34].
Our study shows that VEGF-D could induce tumor












Figure 4 VEGF-D overexpression potentiates lymphatic metastasis of ovarian cancer cell. (A-D) Histologic examination of lymph nodes in
the renal hilum reveals the presence of metastasis (indicated by arrows). (A) and (B) are different fields of view of the same section, and so are (C) and
(D). (E-G) Lymph nodes are immunostained for CA125 (E and F) and CD40 (G). (H-I) Percentage of lymph nodes with metastasis in the sentinel or
total lymph nodes is shown. *P < 0.05 vs. xenografts bearing SKOV3 or SKOV3/pcDNA cells in the sentinel nodes. *P < 0.01 vs. xenografts bearing SKOV3
or SKOV3/pcDNA cells in total lymph nodes. Original magnification: ×400; scale bar = 200 μm. LN, lymph nodes; Met, metastasis.
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nodes. This is likely due to the activation of VEGFR-3
by VEGF-D on the lymphatic endothelium in tumors.
Lymphatic vessel density is found to be higher in cancer
patients with nodal involvement than those without [35].
In our study, lymphatic vessels were clearly seen both
within and at the periphery of tumors, and the lymphatic
vessel density in VEGF-D-transfected tumors was much
higher than that in the controls. The lower lymphatic
vessel density in the central area of tumors compared
to the peripheral area may be due to higher intra-tumoral
interstitial pressure.
Many investigations have focused on the interaction be-
tween VEGF-D and tumor lymphangiogenesis, or lymphan-
giogenesis within lymph nodes [36]. However, few studies
have addressed the role of VEGF-D on lymphatics. In this
study, we used Evan’s blue to examine the lymphatic net-
works in mouse xenografts of ovarian cancer. Intriguingly,
we observed that the draining lymphatic network was
greatly enhanced in mice bearing xenografts overexpressing
VEGF-D. This finding suggests that VEGF-D overexpres-
sion not only promotes intratumoral lymphangiogenesis
but also enhances extratumoral lymphangiogenesis.Lymph drainage from the inguinal to the axillary lymph
node, named the inguinal trunk in rats [37], was occasion-
ally observed in healthy mice [38]. In the current study,
lymphatic vessel enlargement was noticed in 5 out of 6
VEGF-D overexpressing mice. The activation and en-
largement of this originally inefficient vessel system is
attributable to the overexpression of VEGF-D, and can be
explained as a result of VEGFR-3 activation by increased
VEGF-D on the lymphatic endothelium [39,40]. This in-
teresting finding, therefore, indicates a novel mechanism
for VEGF-D in tumor dissemination in ovarian carcinoma
by activating and promoting somatic lymphatic systems,
in addition to increasing lymphangiogenesis within the tu-
mors. This novel link between dilation of the collecting
lymphatic vessels and lymphatic metastasis was also found
in breast cancer, as recently reported by Karnezis et al.
[41]. Further investigations are required to elucidate this
novel mechanism.
In addition to affecting lymphatic endothelial cells, the
role of VEGF-D as an autocrine factor for tumor cells
have been found in some cancers. VEGF-D has been
linked to the CXCL7/CXCR2 axis and tumor cell invasion




Figure 5 VEGF-D overexpression upregulates CA125 in the metastatic lymph nodes. (A) Representative sections for CA125 in lymph nodes
of mice bearing SKOV3 xenograft- (left panel), SKOV3/pcDNA xenograft (mid panel) or SKOV3/VEGF-D xenografts (right panel). (B) Percentage of
CA125-positive area. P < 0.01 vs. mouse bearing SKOV3 or SKOV3/pcDNA xenografts. Each data point represents a single lymph node. Original
magnification: ×400; scale bar = 200 μm.
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mote filopodia formation as well as cancer cell migration
and invasion [43]. Based on the results from the current
study, this autocrine mode apparently is also the case for
tumor metastasis to lymph nodes. Upregulated VEGF-D
was associated with increased intensity and distribution of
ovarian cancer biomarker CA125 in the involved lymph
nodes. CA125 has been used as a tumor marker of ovarian
carcinoma over the last three decades. It is evaluated for
monitoring response to treatment, detecting recurrent
disease, distinguishing malignant from benign pelvic
masses, and for early detection of ovarian carcinoma.
Recently, CA125 has been found to be associated with
an invasive phenotype and the metastatic potential of
ovarian cancer cells, showing its functional role as an
aggressive biomarker for ovarian carcinoma [19,44]. In
the current study, CA125 staining was enhanced in the
lymph nodes of mice bearing xenografts overexpressing
VEGF-D, indicating the role of VEGF-D in promoting
tumor cell invasion.Table 2 CA125 staining intensity in the metastatic
lymph nodes
± + ++
SKOV3 3/5 2/5 0/5
SKOV3/pcDNA 2/6 3/6 1/6
SKOV3/VEGF-D 1/13 3/13 9/13*
*P < 0.01 vs. mice bearing SKOV3 or SKOV3/pcDNA xenografts.The lymphatic endothelium by far is the only site where
VEGFR-3 is reported to be located, suggesting that VEGF-
D mainly exerts its action via lymphatics. Our finding that
VEGF-D promoted tumor growth in vivo could not be
readily explained by interaction of VEGF-D with VEGFR-
3. We also found that VEGF-D suppressed the apoptosis
of ovarian carcinoma cells, suggesting that increased
growth of tumor size may be the consequence of subdued
apoptosis of the tumor cells. In addition, increased growth
of ovarian carcinoma cells further aggravated lymph
node metastasis as tumor size has been regarded as a
stimulating factor for nodal invasion [45-48]. Consist-
ently, Akahane et al. also found that VEGF-D inhibited
apoptosis of breast cancer cells [49]. We found more
apparent angiogenesis in the tumor tissues overexpressing
VEGF-D (data not shown), suggesting its contribution to
accelerated tumor growth [50,51].
Lymph node metastasis involves numerous factors. The
current study suggested that this process could be initiated
and regulated by VEGF-D expressed by tumors. Over-
expression of this factor alone is sufficient to promote tumor
dissemination to the lymph vessel system. Considering
that VEGF-D is overexpressed in human ovarian car-
cinoma, the metastasis progression in our investigation
may mimic the metastatic process in human ovarian
cancer. We also investigated the molecular mechanism
of VEGF-D in promoting lymphogenous metastasis. In
addition to stimulating tumor lymphangiogenesis, VEGF-
D unexpectedly stimulated somatic draining lymphatic
Figure 6 VEGF-D overexpression suppresses apoptosis of ovarian cancer cells. Tumor tissues were stained with Hoechst 33258. Apoptotic
cells are indicated by arrows (A-C). (A) Tumors bearing SKOV3 cells; (B) tumors bearing SKOV3/pcDNA cells; (C) tumors bearing SKOV3/VEGF-D
cells. (D) Apoptosis index of tumor cells. P < 0.05 vs. xenografts bearing SKOV3 or SKOV3/pcDNA.
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ing lymphatics as a gateway in tumor cell dissemination.
Conclusions
In conclusion, the current study demonstrated that VEGF-
D promotes lymphatic metastasis in ovarian cancer.
The findings represent a previously under-appreciated
role of VEGF-D in ovarian cancer dissemination, and
encourage targeted treatment of ovarian cancer via VEGF-
D-mediated pathway.
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